drugset
drugset / Trial / NCT07715084

Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

NCT07715084 ↗

Phase 2 Not yet recruiting 20 enrolled Azafaros B.V.
NaSingle-groupOpen-labelTreatment

Summary

A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).

Timeline

Start
2026-09-28
Primary completion
2028-01
Completion
2029-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nizubaglustat Unknown — Oral

Indications

Gaucher disease type III